
Although dermatologists have embraced mole-mapping techniques, including total body imaging and (to a lesser extent) dermoscopy, they appear to share the Food and Drug Administration's (FDA) concerns that non-dermatologists might misuse the MelaFind (MELA Sciences) device, which an FDA advisory panel recently recommended for approval in a split decision.
